Life Sciences Marketing

Why the Standard B2B Playbook Breaks Down and What Actually Works

Stephan WengerGuide14 minMarch 1st, 2026

Table of Contents

Subscribe to our Newsletter and Learn B2B Marketing.

Life sciences marketing is broken. Not because the tools are wrong or the budgets are too small.

It’s broken because the standard B2B playbook was never built for an audience that peer-reviews your claims before reading your second paragraph.

Your buyers are PhDs, lab directors, and clinicians. They don’t click on “request a demo” because your ad told them to. They read 3 to 7 pieces of content before they even consider talking to sales.

And when they do engage, they bring 6 to 13 colleagues into the decision. Good luck convincing all of them with a single landing page.

Meanwhile, nearly 24% of companies are cutting senior marketing roles without lowering the performance bar. Fewer people, same expectations, harder audience.

This article breaks down why life sciences marketing plays by different rules, which channels actually earn trust with scientific buyers, and where to start when your team is stretched thin.

Life Sciences Marketing Expectations © B2B Marketing World

Scientists Don’t Trust Marketing

Most B2B industries deal with skeptical buyers. Life sciences operates on a completely different level. Your audience isn’t just cautious. They’re trained to be skeptical. Peer review, evidence hierarchies, statistical significance: these aren’t buzzwords for them. It’s how they think. Every day. About everything.

So when your marketing sounds like… well, marketing, they don’t just ignore it. They actively distrust you for it.

That’s the core problem

The people you’re trying to reach have spent years learning how to poke holes in arguments. A bold claim without data? Gone. A whitepaper that reads like a brochure? Closed. A case study without methodology? Not worth their time.

And here’s what makes it worse: they do their homework before you even know they exist. According to research by Demand Gen Report, 62% of B2B buyers in life sciences read 3 to 7 pieces of content before they engage with a sales rep. Your content is your first interview. And your audience grades harder than most. This is why a solid content marketing strategy matters more in life sciences than in almost any other B2B sector.

Now add regulatory pressure on top

The FDA, EMA, and other agencies don’t just regulate products. They regulate what you can say about those products, how you can say it, and when. Every marketing claim goes through legal review. Every piece of collateral needs compliance sign-off. That doesn’t just slow you down. It compresses the creative space your team has to work with into something painfully small.

This leads to an obvious question. How do you simplify complex science for a broad buying committee without dumbing it down for the experts?

Because that’s the real tension.

Simplify too much and you lose credibility

… with the researchers and clinicians who influence the deal. Stay too technical and you lose the procurement team, the finance director, and the C-suite who approve the budget. Life sciences marketing lives in that gap. And most teams haven’t figured out how to navigate it yet.

The logic is simple. If your marketing doesn’t meet the evidence standard your audience applies to everything else in their work, it won’t get read. It won’t get shared. And it definitely won’t move a deal forward.

13 Stakeholders, One Decision

How Life Sciences Buying Committees Stall Deals

You’ve built a great piece of content. The right person reads it. They’re interested. And then… nothing happens for 6 months.

Welcome to life sciences B2B, where the person who loves your product is rarely the person who signs the check.

What to focus on here:

The Buying Committee Is Bigger Than You Think

According to Gartner, a typical buying group for a complex B2B solution involves 6 to 10 decision-makers. Forrester puts that number even higher at 13 stakeholders on average, spread across multiple departments.

Influence of the Life Sciences Buying Center © B2B Marketing World

Each of them brings their own research, their own priorities, and their own reasons to say no. Understanding your B2B marketing funnel and how these stakeholders move through it is essential to avoid stalled deals.

In life sciences, that committee looks something like this:

Role	What they care about	Content they need
C-suite / Finance	ROI, strategic fit, budget impact	Executive summaries, financial models
KOLs / Principal Investigators	Scientific validity, peer evidence	Peer-reviewed data, clinical results
Lab Managers / Technical Buyers	Workflow integration, usability	Application notes, product demos
Procurement / Compliance	Regulatory risk, contract terms	Compliance documentation, certifications
End Users	Daily usability, learning curve	Tutorials, onboarding guides

One message doesn’t work for this group. One content format doesn’t either.

“No Decision” Beats Your Competitor More Often Than You’d Expect

Here’s a stat that should change how you think about your pipeline: over 40% of B2B deals stall because internal stakeholders fail to align (AdvanceB2B). Not because a competitor won. Not because the budget disappeared. The committee simply couldn’t agree.

That means your biggest competitor isn’t the other vendor. It’s indecision.

Each Stakeholder Speaks a Different Language

A CFO asks “what’s the return?” A researcher asks “where’s the data?” A lab manager asks “does it fit our workflow?” These aren’t variations of the same question. They’re fundamentally different concerns. And if your marketing only answers one of them, the deal stalls with the others.

This is where most life sciences marketing teams fall short. They produce content for the researcher because that feels natural. But they forget that the person who influences the deal is not always the person who approves it.

Meanwhile, sales rep access to health systems continues to decline (ZS), which means marketing is often the only voice in the room before any human conversation happens. This dynamic is why lead management — the process of generating, nurturing, and qualifying leads across both marketing and sales — becomes mission-critical in life sciences.

Fair enough. But this only works if you know who’s sitting at that table. And most teams don’t map their buying committees until it’s too late.

Marketing Channels That Work When Your Buyer Has a PhD

Knowing that your audience is skeptical and your buying committee is large doesn’t help much if you’re spending your budget on the wrong channels.

And in life sciences, “wrong” often just means “borrowed from a SaaS playbook without adjusting for the audience.”

So which channels actually earn attention from scientists, researchers, and healthcare professionals? The answer isn’t surprising. But the reasoning behind it matters more than the list itself.

Here they are:

Conferences Are Back

In-person events are back. Both scientists and marketers rank conferences and company-hosted events as a top priority again, after years of virtual fatigue. That part isn’t new.

What’s changed is what “showing up” means. Standing behind a booth and handing out brochures? That’s presence, not strategy.

The companies getting results are treating events as 3-phase campaigns: pre-conference outreach to booked meetings, on-site content capture (talks, demos, interviews), and post-event follow-up sequences that turn badge scans into pipeline.

Email Still Works

Email remains one of the highest-performing digital B2B marketing channels in life sciences. But performance depends almost entirely on segmentation and content quality. A monthly newsletter blasted to your full database? That’s not email marketing. That’s noise.

What works: role-specific sequences triggered by behavior. A lab manager who downloads an application note gets a different follow-up than a procurement lead who viewed a compliance page. The logic here connects directly to your buying committee map. If you’ve done Step 1 (more on that below), your email segmentation almost writes itself.

Webinars Are the New White Paper

In life sciences, webinars have quietly become one of the most effective channels for mid-funnel engagement.

They let you do something almost no other channel can: show expertise in real time. Live Q&A, peer discussion, and the ability to handle technical pushback on the spot. That builds trust in a way a PDF never will.

The catch? They work best when they’re not product-focused. The highest-performing webinars in this space are educational. They address a research challenge, a regulatory shift, or a workflow bottleneck. The product shows up as context, not as the headline.

Account Based Marketing (If you Know the Account)

Account-based marketing sounds perfect for life sciences. Long sales cycles, high deal values, complex buying committees. The fit is obvious. But here’s the gap: ABM falls apart when you don’t have a clear picture of the account’s internal structure. And in life sciences, that structure is harder to map than in most industries.

When it works, it’s powerful. Personalized campaigns targeting 3 to 5 roles within a single health system or pharma company can accelerate pipeline in ways that broad demand generation simply can’t.

But it requires the buying committee map from Step 1. Without it, ABM becomes expensive guesswork. For a deeper dive into this approach, the guide on demand generation marketing covers how ABM fits into a broader demand strategy.

LinkedIn: Useful, but Not as Dominant as You’d Think

LinkedIn is the default B2B channel for most marketers. And it has a role in life sciences too — especially for thought leadership, KOL visibility, and recruitment.

But scientists and clinicians don’t live on LinkedIn the way SaaS buyers do. Their primary channels are still journals, conferences, and peer networks.

Use LinkedIn to amplify. Not as your primary channel.

Emerging Channels Worth Testing

Peer-to-peer influence and KOL partnerships are gaining traction in life sciences marketing. Not “influencers” in the Instagram sense. Key Opinion Leaders, researchers with engaged followings, and scientists who’ve built credibility in a specific niche. When a respected KOL shares or endorses your content, it carries weight that no branded ad ever will. The endorsement isn’t about reach. It’s about borrowed trust.

Branded podcasts and audio content are still underused in life sciences, but the format fits the audience perfectly. Scientists listen. They commute, they work in labs, they travel to conferences. Audio is a low-friction way to build brand affinity without asking for a click, a form fill, or a download. If you’re exploring this channel, the curated list of 30+ B2B marketing podcasts offers useful benchmarks for format and positioning. More on this in the next section.

One more thing that deserves a direct statement: the balance between online and offline is tilted too far toward digital in most life sciences marketing teams. Direct mail to targeted accounts. Print ads in respected medical journals. Field support for sales at key accounts. These “old-school” channels still influence decisions. They’re just harder to measure, so they get cut first. That’s a budgeting mistake, not a strategy decision.

How Educational Content Helps to Reach The Audience Without Classic Marketing Barriers © B2B Marketing World

Branded Podcast: Marketing for Life Sciences

Everything in this article so far points to one core problem: scientists don’t want to be marketed to. They want to learn, discover, and connect with the work. So what happens when a life sciences company stops talking about its products entirely and starts telling the stories of the people behind the science?

Thermo Fisher Scientific did exactly that. Their podcast series doesn’t pitch products. It profiles scientists. Career journeys, research challenges, the human side of working in a lab. No promotional CTAs. No feature comparisons. Just conversations that scientists actually want to listen to.

Podcast as Life Sciences Marketing Channel © Spotify / Thermo Fisher Scientific

And that’s why it works.

It builds brand affinity without ever triggering the “this is an ad” reflex.

There’s a practical bonus too. Because the content makes no product claims, it sidesteps the regulatory compliance bottleneck that slows down almost every other marketing format in life sciences. No legal review of promotional language. No FDA concerns. Just educational content that happens to carry your brand.

Each episode becomes a reusable asset: social clips, newsletter features, blog summaries, conference talking points. The content compounds over time instead of expiring after one campaign cycle.

That’s rare in an industry where most marketing materials have a short shelf life due to regulatory updates and product changes. This concept of content compounding is central to an effective B2B content marketing strategy — whether you choose podcasts, white papers, or educational video.

The takeaway isn’t “start a podcast.”

It’s this: when your audience resists being sold to, stop selling and start being useful. The format matters less than the shift in intent.

What Works in Life Sciences Marketing in 2026

Nearly 24% of brands are cutting senior marketing roles without reducing expectations (Marketing Week, 2025). The teams are shrinking. The job isn’t. So let’s skip the theory and go straight to what to do, in what order.

Step 1: Map your buying committee

This is the foundation. Everything else depends on it.

Identify the 6 to 13 roles that show up in your typical deal. Document what each role cares about and where they drop off. You already know who these people are (we covered them in the buying committee section above).

The work here isn’t research. It’s sitting down with sales, pulling CRM data, and turning tribal knowledge into an actual map your whole team can use. For a structured approach, the B2B marketing strategy guide walks through how to define target groups and buying center personas step by step.

Dependency: Steps 2 and 3 can’t work without this. If you skip the map, you’ll build content and choose channels based on assumptions, not evidence.

Step 2: Audit your content against the map

Most life sciences marketing teams don’t have a content problem. They have a coverage problem. You’ll likely find 80% of your existing content speaks to one or two roles while the rest of the committee gets nothing.

The audit reveals the gaps. Once you see them, prioritize filling the ones that block deals most often. That’s usually the role that says no, not the role that says yes. Whether to gate or ungate that content is the next decision — and it depends on where each role sits in the buying process.

Dependency: An audit without the map from Step 1 is just an inventory. It tells you what you have, not what’s missing.

Step 3: Match channels to the committee, not to your comfort zone

Pick 2 to 3 proven channels (email, webinars, conferences) and add one emerging channel to test: ABM for your top accounts, a KOL partnership, or a pilot podcast series. The selection criteria isn’t “what’s trending.” It’s “where does my buying committee actually spend attention?” Run it for 6 months. Measure. Then scale or stop. To streamline this planning, the free B2B marketing templates — including a marketing plan template and content calendar — can save significant setup time.

Dependency: Channel selection without Step 1 and Step 2 means you’re distributing the wrong content to the wrong people. The sequence matters.

The waterfall logic looks like this:

Buying committee map → content audit against the map → targeted channel selection.

Each step feeds the next. Skip one and the rest falls apart. Go back to Step 1 when deals stall and you don’t know why. Go back to Step 2 when content exists but doesn’t convert. Go back to Step 3 when reach is fine but engagement is flat.

That’s the diagnostic built into the sequence. It’s not just a launch plan. It’s a troubleshooting framework you can run every quarter.

The biggest risk for life sciences marketing teams isn’t choosing the wrong tactic.

It’s doing too many things at 30% instead of 3 things at 100%.

Summary [TL;DR]

You sell to scientists. That changes everything.

Your buyers peer-review your content before they’ll even talk to sales. They read 3 to 7 pieces before engaging. They bring 6 to 13 colleagues into every decision. And over 40% of those deals don’t stall because a competitor won. They stall because the buying committee couldn’t agree.

If you take nothing else from this article, take these 5 things:

Your audience is trained to distrust marketing. Peer-reviewed evidence, real data, and scientific rigor aren’t nice-to-haves. They’re the entry ticket. Anything that reads like a brochure gets dismissed.
Your biggest competitor is “no decision.” Buying committees in life sciences are large, cross-functional, and slow. If your content only speaks to one role, the deal dies with the others.
Proven channels still carry the weight. Email, webinars, white papers, and conferences aren’t exciting. They work. Especially when you segment by role and treat conferences as 3-phase campaigns, not booth rentals.
Stop selling. Start being useful. The branded podcast model proves it: when you tell the stories scientists care about instead of pitching products, you bypass the trust barrier and the compliance bottleneck at the same time.
Follow the waterfall. Map the buying committee first. Audit your content against that map second. Choose channels third. Each step feeds the next. Skip one and the rest collapses.

The life sciences market is projected to nearly triple by 2034 (Precedence Research). The opportunity is massive. But the teams chasing it are getting smaller, not bigger. Nearly 1 in 4 companies have cut senior marketing roles without lowering the bar.

That means you can’t afford to do everything. But you also can’t afford to guess.

Start with the buying committee. Build content that earns trust. Put it where your audience actually is. That’s not a theory. That’s a Monday morning action plan.

Life sciences marketing doesn’t need more tools. It needs more clarity. This article gave you the map.

Now use it.

Read full Bio

Stephan Wenger

B2B Marketing Expert, Editor and Marketing Management Consultant

Stephan Wenger is a seasoned B2B Marketing Expert with more than 15 years of experience in leading global companies. His extensive expertise lies in the realms of B2B online marketing, content marketing, strategic marketing, and driving synergy between sales and marketing, including effective lead management.